Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL5562655 | 1.00 | CHRM1 (0.47) | CHRM1HRH1PAK1 | |
| SCHEMBL14511276 | 0.94 | CHRM1 (0.53) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL4840787 | 0.91 | CHRM1 (0.47) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL4840782 | 0.91 | CHRM1 (0.47) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL5558653 | 0.90 | HRH1 (0.49) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL5558647 | 0.90 | HRH1 (0.49) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL5563931 | 0.87 | CHRM1 (0.42) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL5563925 | 0.87 | CHRM1 (0.42) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL4845741 | 0.86 | CHRM1 (0.42) | CHRM1HRH1PAK1 | |
| Succinic Acid SCHEMBL4845732 | 0.86 | CHRM1 (0.42) | CHRM1HRH1PAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1492794-B1 | PIPERAZINE SUBSTITUTED ARYL BENZODIAZEPINES AND THEIR USE AS DOPAMINE RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS | LILLY CO ELI (US) | 2007-12-12 | — | — | EP | disclosed |
| US-7214673-B2 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY (US) | 2007-05-08 | — | — | US | disclosed |
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | ELI LILLY AND COMPANY | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203296-A1 | For therapy of psychosis and bipolar disorder | DRD4, AFF4, DRD2 | HRH1 201/4885CHRM1 203/4885PAK1 4216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.